TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Allarity Therapeutics ( (ALLR) ) has provided an announcement.
On August 26, 2025, Allarity Therapeutics announced that the FDA granted Fast Track designation to stenoparib, their investigational treatment for advanced ovarian cancer. This designation is intended to expedite the development and review process, highlighting the significant unmet need in this area and the potential of stenoparib to improve treatment outcomes. The company recently began enrolling patients in a new Phase 2 clinical trial for stenoparib, aiming to accelerate its clinical development, building on previous encouraging data.
The most recent analyst rating on (ALLR) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.
Spark’s Take on ALLR Stock
According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.
Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.
To see Spark’s full report on ALLR stock, click here.
More about Allarity Therapeutics
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments. The company is dedicated to the development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to create a companion diagnostic for patient selection. Headquartered in the U.S. with a research facility in Denmark, Allarity aims to address significant unmet medical needs in cancer treatment.
Average Trading Volume: 6,570,859
Technical Sentiment Signal: Sell
Current Market Cap: $20.91M
Learn more about ALLR stock on TipRanks’ Stock Analysis page.